Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 21, 2012; 18(11): 1159-1165
Published online Mar 21, 2012. doi: 10.3748/wjg.v18.i11.1159
Published online Mar 21, 2012. doi: 10.3748/wjg.v18.i11.1159
Table 2 Areas requiring further investigation
Pharmacologic therapy prior to endoscopy | Determine optimal route and dosage of PPI in UGIH (continuous infusion vs intermittent IV bolus vs oral dosing) |
Timing of endoscopic evaluation | Defining optimal timing of initial endoscopy, implementation of early discharge in low risk patients |
Prokinetic agents as endoscopic adjuncts | Clearly define the role for prokinetics in UGIH with randomized controlled trials, specifically define the optimal agent, dose and timing prior to endoscopy |
Long-term PPI management | Clarification of potential long-term sequelae of PPI including: osteoporosis, c. difficile infection and community-acquired pneumonia |
PPI and thienopyridines | Consensus on the clinical importance of this interaction, a complete randomized controlled trial to support the truncated COGENT trial data |
H. pylori and UGIH | H. pylori testing that allows accurate test results in the setting of acute UGIH |
- Citation: Trawick EP, Yachimski PS. Management of non-variceal upper gastrointestinal tract hemorrhage: Controversies and areas of uncertainty. World J Gastroenterol 2012; 18(11): 1159-1165
- URL: https://www.wjgnet.com/1007-9327/full/v18/i11/1159.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i11.1159